As the European markets show signs of resilience, with the STOXX Europe 600 Index climbing 1.32% amid easing geopolitical tensions and promises of economic stimulus, investors are keenly assessing opportunities in the region. Identifying undervalued stocks can be particularly appealing in such an environment, as these equities may offer potential for growth when market conditions stabilize further.
| Name | Current Price | Fair Value (Est) | Discount (Est) |
| Zaptec (OB:ZAP) | NOK22.50 | NOK44.90 | 49.9% |
| Qt Group Oyj (HLSE:QTCOM) | €57.55 | €113.35 | 49.2% |
| Laboratorios Farmaceuticos Rovi (BME:ROVI) | €55.75 | €110.26 | 49.4% |
| Ion Beam Applications (ENXTBR:IBAB) | €11.66 | €22.99 | 49.3% |
| innoscripta (XTRA:1INN) | €99.30 | €196.58 | 49.5% |
| Honkarakenne Oyj (HLSE:HONBS) | €2.70 | €5.37 | 49.7% |
| Green Oleo (BIT:GRN) | €0.795 | €1.57 | 49.2% |
| Cavotec (OM:CCC) | SEK17.00 | SEK33.97 | 49.9% |
| Archicom (WSE:ARH) | PLN43.00 | PLN84.73 | 49.2% |
| ABO Energy GmbH KGaA (XTRA:AB9) | €38.40 | €76.54 | 49.8% |
Underneath we present a selection of stocks filtered out by our screen.
Overview: Laboratorios Farmaceuticos Rovi, S.A. is a pharmaceutical company that manufactures, sells, and markets its products across Spain, the European Union, OECD countries, and internationally with a market cap of €2.85 billion.
Operations: Laboratorios Farmaceuticos Rovi generates revenue through the manufacturing, selling, and marketing of pharmaceutical products across Spain, the European Union, OECD countries, and internationally.
Estimated Discount To Fair Value: 49.4%
Laboratorios Farmaceuticos Rovi is trading at €55.75, significantly below its estimated fair value of €110.26, indicating it may be undervalued based on cash flows. Analysts agree the stock price could rise by 41.8%. With earnings forecast to grow 16.5% annually—outpacing the Spanish market's 5.5%—and revenue projected to increase at 8.2%, Rovi's financial outlook remains robust despite slower-than-significant growth expectations in both earnings and revenue metrics.
Overview: Neste Oyj, with a market cap of €9.22 billion, operates in the production and distribution of renewable diesel and sustainable aviation fuel across Finland, other Nordic countries, the Baltic Rim, Europe, the United States, and internationally.
Operations: The company's revenue segments include Oil Products (€12.10 billion), Renewable Products (€7.30 billion), and Marketing & Services (€4.51 billion).
Estimated Discount To Fair Value: 19.6%
Neste Oyj is trading at €12, below its estimated fair value of €14.92, reflecting a modest undervaluation based on discounted cash flow analysis. Despite recent volatility and high debt levels, the company is expected to achieve profitability within three years with earnings projected to grow significantly annually. Recent developments in renewable fuel technology with Chevron Lummus Global highlight potential future revenue streams, although recent index exclusion may impact investor sentiment.
Overview: Andritz AG is a global provider of industrial machinery, equipment, and services across various continents including Europe, North America, South America, China, Asia, Africa, and Australia with a market cap of €5.99 billion.
Operations: The company generates revenue from four main segments: Metals (€1.78 billion), Hydro Power (€1.61 billion), Pulp & Paper (€3.27 billion), and Environment & Energy (€1.52 billion).
Estimated Discount To Fair Value: 48.3%
Andritz AG, trading at €61.5, is significantly undervalued with an estimated fair value of €118.95 based on discounted cash flow analysis. Despite a decline in first-quarter sales and net income compared to the previous year, earnings are projected to grow 11.47% annually, outpacing the Austrian market's growth rate. However, its dividend yield of 4.23% is not fully supported by free cash flows, indicating potential sustainability concerns despite strong relative value against industry peers.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com